Medical Device Software Under the EU MDR

by | Sep 9, 2019 | EU, EU MDR, FDA, Medical Devices, Regulatory, Requirements, Software

With the up-classification of medical devices as per the new EU MDR, software used as a medical device has been affected the most.

Under Rule 11:

“Software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes is classified as class IIa, except if such decisions have an impact that may cause: death or an irreversible deterioration of a person’s state of health, in which case it is in class III; or a serious deterioration of a person’s state of health or a surgical intervention, in which case it is classified as class IIb.

Software intended to monitor physiological processes is classified as class IIa, except if it is intended for monitoring of vital physiological parameters, where the nature of variations of those parameters is such that it could result in immediate danger to the patient, in which case it is classified as class IIb. All other software is classified as class I.1

This new classification scheme will affect the software currently classified as class I. Furthermore, article 2 of the MDR defines software as an active medical device. “Active device’ means any device, the operation of which depends on a source of energy other than that generated by the human body for that purpose, or by gravity, and which acts by changing the density of or converting that energy.” Since software needs energy in the form of electricity to function, it is an active device.1

With the new classification scheme, very few software will be left in the class I category, leaving the majority of the software as a medical device to be bumped up to class IIA.

What does this mean?

Companies whose products have been up-classified from class I to class IIa will now have to involve notified bodies. They will also be required to establish a certified quality system. The other thing to consider is during the transition period for the EU MDR, legacy devices with a CE mark under the MDD can be marketed in the EU. However, class I medical devices including software that has been now up-classified under the EU MDR to class IIa cannot leverage their MDD certificate to be marketed in the EU during that grace period. A valid CE mark issued by a Notified Body must be in place to be eligible for the EU MDR grace period.2

Need help with your EU MDR transition? Call us today at 248-987-4497 or email us at


of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC retrieved on 09/05/2019 from


Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

Pattern Recognition as a Quality Superpower

Pattern Recognition as a Quality Superpower

There are always new ways and reasons to apply pattern recognition to quality improvement. Better ensuring patient outcomes in health care facilities and improving accuracy for medical diagnoses are two such frontiers.
Record Control for a Regulated World

Record Control for a Regulated World

In a regulated industry, the prevailing posture of regulatory representatives, in my experience, has been “Show me proof.” In fact, the philosophy I’ve heard repeated by regulators is “If it wasn’t documented, it didn’t happen.”
EU MDR SSCP’s: The Importance of Readability

EU MDR SSCP’s: The Importance of Readability

Among many of the new requirements that EU MDR has introduced, the Summary of Safety and Clinical Performance (SSCP) is certainly one of the more confusing ones for many firms. SSCP’s are required for implantable and Class III devices under EU MDR and is intended to be a public document summarizing important safety and clinical performance information about the device.

Ready to learn more about working with us?

Pin It on Pinterest

Share This